Related references
Note: Only part of the references are listed.Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
Ana Bety Enriquez et al.
JAMA OPHTHALMOLOGY (2021)
Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study
Manuel Saenz-de-Viteri et al.
ACTA OPHTHALMOLOGICA (2021)
Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
Alper Bilgic et al.
JOURNAL OF CLINICAL MEDICINE (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Richard P. Gale et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
Caroline R. Baumal et al.
OPHTHALMOLOGY (2020)
Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
Jaycob Avaylon et al.
INTERNATIONAL MEDICAL CASE REPORTS JOURNAL (2020)
Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice
Luciana de Sa Quirino-Makarczyk et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2020)
Innovative therapies for neovascular age-related macular degeneration
Hasenin Al-Khersan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
Robyn H. Guymer et al.
OPHTHALMOLOGY (2019)
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
Rehan M. Hussain et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice
Raphaelle Despreaux et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2016)